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Summary
Age-related macular degeneration (AMD) is the most
common geriatric eye disorder leading to blindness and
is characterized by degeneration of the neuroepithelium
in the macular area of the eye. Apolipoprotein E (apoE),
the major apolipoprotein of the CNS and an important
regulator of cholesterol and lipid transport, appears to
be associated with neurodegeneration. The apoE gene
(APOE) polymorphism is a strong risk factor for various
neurodegenerative diseases, and the apoE protein has
been demonstrated in disease-associated lesions of these
disorders. Hypothesizing that variants of APOE act as
a potential risk factor for AMD, we performed a genetic-
association study among 88 AMD cases and 901 con-
trols derived from the population-based Rotterdam
Study in the Netherlands. The APOE polymorphism
showed a significant association with the risk for AMD;
the APOE e4 allele was associated with a decreased risk
(odds ratio 0.43 [95% confidence interval 0.21–0.88]),
and the e2 allele was associated with a slightly increased
risk of AMD (odds ratio 1.5 [95% confidence interval
0.8–2.82]). To investigate whether apoE is directly in-
volved in the pathogenesis of AMD, we studied apoE
immunoreactivity in 15 AMD and 10 control maculae
and found that apoE staining was consistently present
in the disease-associated deposits in AMD-maculae–that
is, drusen and basal laminar deposit. Our results suggest
that APOE is a susceptibility gene for AMD.
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Introduction
Age-related macular degeneration (AMD) is the most
common cause of blindness in the elderly in developed
countries (Sommer et al. 1991; Klein et al. 1995; Attebo
et al. 1996; Klaver et al. 1998), severely affecting 110%
of octo- and nonagenarians (Vingerling et al. 1995). His-
topathologically, the hallmark of early AMD is accu-
mulation of extracellular drusen and basal laminar de-
posit (van der Schaft et al. 1992; Green and Enger 1993;
Kliffen et al. 1997); the end stage is characterized by a
complete degeneration of the neurosensory retina and
of the underlying retinal pigment epithelium in the mac-
ular area (Sarks 1976). The etiology of AMD is largely
unknown, but the current understanding is that AMD
is a genetically complex eye disorder (Heiba et al. 1994;
Klaver et al. 1997; Seddon et al. 1997) possibly caused
by a variety of molecular defects. Less frequent macular
disorders have been linked to a significant number of
genomic loci (Small et al. 1992, 1996; Stone et al. 1992,
1994; Evans et al. 1994; Gregory et al. 1996), whereas
mutations in the TIMP3 (Weber et al. 1994) and peri-
pherin/RDS (Nichols et al. 1993; Weleber et al. 1993;
Wells et al. 1993; Keen et al. 1994; Nakazawa et al.
1994; Hoyng et al. 1996) genes have been identified in
specific earlier-onset retinal dystrophies. Despite close
clinical similarities between AMD and these disorders,
neither the TIMP3 gene nor the peripherin/RDS gene
has been associated with AMD. A recent publication
reports that the Stargardt disease gene shows a consistent
variation of the ABCR gene in 4.2% of AMD patients,
significantly different from the 0.45% in population con-
trols (Allikmets et al. 1997). This variation may account
for ∼4% of the total occurrence of AMD, and, presum-
ably, more genes are involved.
Apolipoprotein E (apoE) is unique among apolipo-
proteins, in its special relevance to nervous tissue. It mo-
bilizes and redistributes lipids, inmaintenance and repair
of neuronal cell membranes (Pitas et al. 1987; Mahley
1988; Boyles et al. 1989), thereby playing a pivotal role
in the reinnervation process following peripheral nerv-
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Table 1
Distribution of APOE Genotypes and Allele Frequency
APOE CHARACTERISTIC
FREQUENCY IN
AMD Cases
(n  88)
Controls
(n  901)
Genotype:
E2E2 .000 .010
E2E3 .227 .144
E2E4 .023 .017
E3E3 .636 .555
E3E4 .114a .252
E4E4 .000 .022
Allele frequency:
e2 .125 .090
e3 .806 .753
e4 .068b .156
a P  .02, compared with controls.
b P  .004, compared with controls. Hardy-Weinberg equilibrium:
cases x2  2.27, P  .26; controls x2  4.24, P  .11.
ous system (Ignatius et al. 1986) and CNS injury (Poirier
et al. 1993). The gene for apoE (APOE), located on
chromosome 19q13.2 (Olaisen et al. 1982), is poly-
morphic, with the occurrence of three common alleles:
e2, e3, and e4. The e3 allele is considered to be the
ancestral allele; and e2 and e4 are considered as variants,
on the basis of single point mutations (Mahley 1988).
APOE’s polymorphism is of particular interest within
the framework of neurodegeneration, for it is strongly
associated with the risk of Alzheimer disease (Stritt-
matter et al. 1993; Farrer et al. 1997) and may be as-
sociated with various other neurodegenerative disorders
(Amouyel et al. 1994; Al-Chalabi et al. 1996).Moreover,
apoE is expressed in lesions that characterize Alzheimer
disease, Down syndrome, and prion diseases (Namba et
al. 1991; Wisniewski and Frangione 1992).
Expanding these data to a neurodegenerative eye dis-
order, we investigated the possible role of APOE in AMD
in a genetic-association study. We have used a case-con-
trol design implemented within a population-based
study, to assess whether the APOE alleles are associated
with the risk of AMD. In a subsequent immunohisto-
chemical procedure, we studied apoE expression in hu-
man maculae with and without AMD.
Subjects and Methods
We studied APOE genotype and allele frequencies in
AMD cases and in controls in the Rotterdam Study, a
population-based study, in the Netherlands, of subjects
age x55 years. The rationale and design of the Rotter-
dam Study have been described elsewhere (Hofman et
al. 1991; Vingerling et al. 1995). A total of 6,775 par-
ticipants in that study had undergone an extensive oph-
thalmological examination, including fundus photog-
raphy. Diagnosis of AMD was based on grading of
fundus transparencies according to an internationally
accepted classification system (Bird et al. 1995). Cases
were all subjects with end stages of AMD on whom data
on APOE genotype were available (n  88). The end
stages comprised atrophic macular degeneration—that
is, geographic areas of atrophy of the retinal pigment
epithelium and choriocapillaris—and neovascular mac-
ular degeneration—that is, serous or hemorrhagic de-
tachment of the pigment epithelium or choroidal neo-
vascularization. Controls were a randomly selected
sample of study subjects without atrophic or neovascular
AMD (n  901). There were no significant differences,
in baseline characteristics, between cases and controls,
apart from the known risk factors age and atheroscle-
rosis (mean age [SD] 81 [8] vs. 69 [9] years, P ! .001;
frequency of lower-extremity arterial disease [an indi-
cator of atherosclerosis] 37% vs. 16%, P ! .001 [age-
adjusted prevalence data]).
Genomic DNA was extracted from peripheral blood
leukocytes, and the subsequent analysis of APOE geno-
types was performed as described elsewhere (Wenham
et al. 1991; van Duijn et al. 1994). Genotype and allele
distributions between cases and controls were calculated
by use of x2 statistics. With multiple logistic-regression
analysis, we estimated the odds ratio (OR), as a measure
of relative risk, for the various genotypes, using the an-
cestral E3E3 genotype as a reference. ORs were adjusted
for age and gender and, in a separate analysis, for the
presence of lower-extremity arterial disease, to investi-
gate the possible confounding effect of atherosclerosis.
For the immunohistochemical study, maculae were
obtained from 25 human eye-bank eyes from 25 sub-
jects. The times from death to processing of the maculae
were 1–10 h, with a mean of 7 h. Tissues were fixed in
4% formaldehyde, embedded in paraffin, and sectioned
into 5-mm thicknesses. Sections were stained with he-
matoxylin-eosin, the periodic-acid–Schiff reaction, and
Mallory staining and subsequently were classified his-
tologically according to quantification of drusen and
basal laminar deposit, as described elsewhere (van der
Schaft et al. 1992; Kliffen et al. 1997). Accordingly,mac-
ulae with no or only solitary patches of basal laminar
deposit and with no more than three drusen were clas-
sified as controls (n  10); and maculae with a contin-
uous layer of basal laminar deposit and/or with many
or confluent drusen were classified as cases (n  15).
Cases were, although not significantly, older than con-
trols (mean age [SD] 82 [10] vs. 72 [14] years; P  .08).
After deparaffinization and rehydration, sections were
incubated with 5.5 mU/ml pronase E (Sigma), to reveal
antigenic epitopes of APOE, and were placed in a Se-
quenza Immunostaining Workstation (Life Sciences In-
ternational). Sections were successively incubated with
a mouse-monoclonal antibody directed against apoE
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Figure 1 APOE allele frequencies in the age categories of 55–75
years, 75–85 years, and 185 years: the number of cases and the number
of controls, respectively, in these successive categories are 17 and 687,
40 and 188, and 26 and 31.
Table 2
Relative Risk of AMD for the APOE Genotypes
APOE GENOTYPEa
NO. OF
OR (95% CONFIDENCE
INTERVAL)
AMD Cases
(n  88)
Controls
(n  901) Crude Adjustedb
E*2 22 154 1.28 (.75–2.21) 1.50 (.80–2.82)
E3E3 56 500 Reference Reference
E*4 12 262 .41 (.22–.78) .43 (.21–.88)
a APOE genotypes with the e2 allele are grouped, and genotypes with the e4 allele
are grouped; subjects with the E2E4 genotype (2 of 88 cases, 15 of 901 controls) are
present in both the E*2 group and the E*4 group.
b For age and gender.
(clone 3D12, dilution 1:25; Monosan), biotinylated-sec-
ondary antibodies (Multilink, dilution 1:75; Biogenex),
and alkaline-phosphatase–conjugated streptavidin (di-
lution 1:50; Biogenex). Between these incubations, sec-
tions were washed thoroughly with PBS. After a final
rinsing with 0.2 M Tris-HCl pH 8.0, the presence of
apoE was visualized with 0.3% New Fuchsin/Tris-HCl
(Sigma).
Results
APOE genotype and allele distributions differed sig-
nificantly between cases and controls (table 1). Com-
pared with controls, the frequency of the APOE e4 allele
was significantly lower among cases (.07 in cases vs. 0.16
in controls; P  .002), whereas the frequency of the e2
allele was, although not significantly, higher (.13 vs. .09;
P  .17 ). Because the e4 allele may adversely affect
longevity, given its association with Alzheimer disease
and coronary heart disease (Kervinen et al. 1993), we
investigated the prevalence of the APOE alleles, as a
function of age (fig. 1). There were no significant dif-
ferences in allele frequencies in the three age groups,
indicating that our findings cannot be explained by the
age-distribution difference between cases and controls.
Table 2 shows the relative risks of AMD, for the dif-
ferent APOE alleles. When adjustment was made for age
and sex, subjects with the e4 allele were more than two
times less likely to develop AMD than were subjects with
the E3E3 genotype. Subjects with the e2 allele were at
a slightly, but not significantly, increased risk of AMD.
Additional adjustment, for lower-extremity arterial dis-
ease, did not significantly alter the risk estimates (data
not shown), suggesting that APOE and atherosclerosis
are independent risk factors for AMD.
apoE immunoreactivity was present in the extracel-
lular deposits that characterized the AMD macu-
lae—that is, basal laminar deposit and soft drusen. Basal
laminar deposit stained positive for apoE in 13 of 15
maculae with this type of deposit (fig. 2A), and drusen
stained positive in 9 of 11 maculae with drusen (fig. 2B).
One eye with atrophic AMD showed both a thick layer
of basal laminar deposit and drusen staining positive for
apoE (fig. 2C). In both case and control maculae, stain-
ing was seen in the outer collagenous zone of Bruch’s
membrane, in blood vessels, and in Mu¨ller cells. Partic-
ularly of interest is the finding that solitary, hard hyaline
drusen, a type of deposit that is clinically not associated
with AMD, did not show any apoE immunoreactivity.
Discussion
Our results show that the APOE polymorphism is sig-
nificantly associated with the risk of AMD and that apoE
is expressed in lesions that characterize AMD. A de-
creased risk of AMD was associated with the e4 allele,
whereas an increased risk was associated with the e2
allele. The consistent immunoreactivity in soft drusen
and basal laminar deposit in the AMD maculae suggests
the importance of apoE in the pathogenesis of AMD.
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Figure 2 Immunohistochemistry of apoE in human maculae with AMD. Shown is positive staining (red), of (A) a thin layer of basal
laminar deposit located between the retinal pigment epithelium (rpe) and Bruch’s membrane (arrow), (B) soft drusen (arrows), and (C) thick
layer of diffuse drusen in a subject with atrophic AMD (note disappearance of the photoreceptors and of most of the rpe). ONL  outer
nuclear layer; and PH  photoreceptors. (New Fuchsin; #400)
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We carefully avoided selection bias, a frequently en-
countered problem in association studies. Since cases
and controls were both derived from the same homo-
geneous source population, and since the distribution of
the APOE genotypes in cases and controls was in Hardy-
Weinberg equilibrium, selection on the basis of genotype
is unlikely. Moreover, the allele frequencies among the
controls were in close agreement with the average allele
frequencies estimated for the Dutch (Smit et al. 1988)
and other Caucasian populations (Davignon et al. 1988).
Because our extensive ophthalmologic examination de-
manded attentiveness from the study subjects, it may
have selected against other neurodegenerative dis-
eases—such as Alzheimer disease—which are known to
be associated with increased e4 frequency. Nevertheless,
this cannot account for allele-frequency differences be-
tween cases and controls, because both groups under-
went identical procedures. Finally, we showed that allele
frequencies were similar across all age groups (fig. 1),
indicating that the association cannot be explained on
the basis of age.
Given the limited amount of data available, we can
only speculate on the possible role of apoE in the neu-
ronal dynamics of the macular area. In the CNS in gen-
eral, a major physiological role for apoE is to mediate
the interaction between apoE-containing lipoproteins
and lipoprotein receptors, including the LDL receptor
(Goldstein et al. 1983) and the LDL receptor–related
protein receptor (LRP) (Kowal et al. 1989). After neu-
ronal cell loss, large amounts of lipids are released from
degenerating cell membranes and myelin, and, in re-
sponse, astrocytes synthesize apoE, to bind the free cho-
lesterol and lipids and to distribute them for reuse in
cell-membrane biosynthesis (Poirier et al. 1993, 1995).
ApoE may have a significant role in retinal membrane
renewal. The high turnover of photoreceptormembranes
(Grindle and Marshall 1978), especially in the macular
area, makes cell-membrane remodeling of critical im-
portance for maintaining the normal physiology of the
retina. Failure of this process may then result in macular
degeneration.
In the CNS, apoE is primarily synthesized by themajor
glial cell, the astrocyte. In our series, cell bodies of the
Mu¨ller cell, the retinal analogue of the astrocyte, showed
significant apoE expression, which may indicate a site
of apoE production. This assumption is supported by
findings from previous reports, which show that these
cells are capable of apoE synthesis (Amaratunga et al.
1996) and which show increased expression in eyes with
retinal damage (Kuhrt et al. 1997). The distribution of
the LDL or LRP receptor in the neuroepithelium of the
eye is unknown, and it is therefore unclear which cells
are able to take up and process apoE-complexed mol-
ecules in this compartment. The retinal pigment-epithe-
lium cell, which has digestion of photoreceptor outer
segments as its primary function, may be an appropriate
candidate.
Interestingly, we found a reduced AMD risk for sub-
jects carrying the e4 allele, whereas for most other neu-
rodegenerative disorders the risk is increased for these
subjects. Isoform-specific alterations in apoE-lipoprotein
metabolism consist of differences in net charge (Davig-
non et al. 1988) and in total serum level (Utermann
1985) and brain level (Bertrand et al. 1995) of apoE.
Recently, it has been shown that the isoforms also differ
in cell-specific binding properties (Guillaume et al.
1996). apoE-mediated binding, internalization, and deg-
radation of lipids in the CNS appear to be different for
each apoE isoform, depending on the type of target cell.
A possible interpretation of our findings is that apoE
isoforms in the macular area may either differ in binding
affinity or elicit a response different than that at other
sites in the nervous system. Since it is not immediately
clear how the APOE alleles may be a source of genetic
risk for AMD, it will be intriguing to investigate whether
accumulation of deposits in AMD occurs in an isoform-
dependent manner.
An alternative explanation for our findings is that the
e4 allele is associated with a distinct mutation in a gene
in linkage disequilibrium with APOE. This may be the
gene that actually determines susceptibility to AMD. Ac-
cording to the August 1997 OMIM (Online Mendelian
Inheritance in Man), 20–30 genes are located in the im-
mediate vicinity of APOE, and they may be considered
in this context; among these genes, we could not find
an obvious candidate gene for retinal disease.
To conclude, we have shown a significant association
between APOE and AMD in a general population of
elderly people, and we have immunohistochemically lo-
calized apoE in defining lesions of AMD. Although in
need of confirmation, our data further emphasize the
role of APOE in neurodegeneration and may indicate
that we have identified a susceptibility gene for AMD.
Acknowledgments
This work was presented at the Macula Society meeting in
Tucson, February 22, 1998. We thank the Bio Implant Services
Foundation and the cornea bank of the Netherlands Oph-
thalmic Research Institute, for assistance in obtaining post-
mortem eyes; Anita Wehnert and Hubert Backhovens, for ge-
notyping; Ada Hooghart and Corina Brussee, for grading
fundus transparencies; and Jacqueline Assink and Arthur Ber-
gen, for constructive review of the manuscript. This work was
supported by the Nestor program (Ministry of Health and
Ministry of Education); the Netherlands Organization for Sci-
entific Research; Topcon Europe BV; the Netherlands Society
for Prevention of Blindness; Landelijke Stighting voor Blinden
en Slechtzienden; Stichting Fondsenwervingsacties Volksge-
zondheid; Stichting Blindenpenning; Rotterdamse Vereniging
voor Blindenbelangen; Stichting Physicotherapeutisch Insti-
Klaver et al.: Apolipoprotein E and Age-Related Macular Degeneration 205
tuut; Stichting voor Ooglijders; Stichting Blindenhulp; Sticht-
ing Rotterdamse Oogheelkundige Onderzoeks Stichting; Flem-
ish Biotechnology Programme grant COT-04; and G.Ph.
Verhagenstichtung.
Electronic-Database Information
Online Mendelian Inheritance in Man (OMIM), http://
www.ncbi.nlm.nih.gov/Omim
References
Al-Chalabi A, Enayat ZE, Bakker MC, Sham PC, Ball DM,
Shaw CE, Lloyd CM, et al (1996) Association of apolipo-
protein E e4 allele with bulbar-onset motor neuron disease.
Lancet 347:159–160
Allikmets R, Shroyer NF, Singh N, Seddon JM, Lewis RA,
Bernstein PS, Peiffer A, et al (1997) Mutation of the Star-
gardt disease gene (ABCR) in age-related macular degen-
eration. Science 277:1805–1807
Amaratunga A, AbrahamCR, Edwards RB, Sandell JH, Schrei-
bert BM, Fine RE (1996) Apolipoprotein E is synthesized
in the retina by Mu¨ller glial cells, secreted into the vitreous,
and rapidly transported into the optic nerve by retinal gan-
glion cells. J Biol Chem 271:5628–5632
Amouyel P, Vidal O, Launay JM, Laplanche JL (1994) The
apolipoprotein E alleles as major susceptibility factors for
Creuzfeldt-Jakob disease: the French research group on ep-
idemiology of human spongiform encephalopathies. Lancet
344:1315–1318
Attebo K, Mitchell P, Smith W (1996) Visual acuity and the
causes of visual loss in Australia. Ophthalmology 103:
357–364
Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM (1995)
Association between apolipoprotein E genotype with brain
levels of apolipoprotein E and apolipoprotein J (clusterin)
in Alzheimer’s disease. Mol Brain Res 33:174–178
Bird AC, Bressler NM, Bressler SB, Chishol IH, Coscas G,
Davis MD, de Jong PTVM, et al (1995) An international
classification and grading system for age-related maculo-
pathy and age-related macular degeneration: the Interna-
tional ARM Epidemiological Study Group. Surv Ophthal-
mol 39:367–374
Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE,
Weisgraber KH, Hui DY, et al (1989) A role for apolipo-
protein E, apolipoprotein A-I, and low density lipoprotein
receptors in cholesterol transport during regeneration and
remyelination of the rat sciatic nerve. J Clin Invest 83:
1015–1031
Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E poly-
morphism and atherosclerosis. Arteriosclerosis 8:1–21
Evans K, Fryer A, Inglehearn C, Duvall-Young J, Whittaker
JL, Gregory CY, Butler R, et al (1994) Genetic linkage of
cone-rod retinal dystrophy to chromosome 19q and evidence
for segregation distortion. Nat Genet 6:210–213
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA,
Mayeux R, Myers RH, et al (1997) Effects of age, sex, and
ethnicity on the association between apolipoprotein E ge-
notype and Alzheimer disease: a meta-analysis. JAMA 278:
1349–1356
Goldstein JL, Basu SK, Brown MS (1983) Receptor-mediated
endocytosis of low-density lipoprotein in cultured cells.
Methods Enzymol 98:241–261
Green WR, Enger C (1993) Age-related macular degeneration
histopathologic studies: the 1992 Lorenz E. Zimmerman
Lecture. Ophthalmology 100:1519–1535
Gregory CY, Evans K, Wijesuriya SD, Kermani S, Jay MR,
Plant C, Cox N, et al (1996) The gene responsible for au-
tosomal dominant Doyne’s honeycomb retinal dystrophy
(DHRD) maps to chromosome 2p16. Hum Mol Genet 5:
1055–1059
Grindle CFJ, Marshall J (1978) Ageing changes in Bruch’s
membrane and their functional implications. TransOphthal-
mol Soc UK 98:172–175
Guillaume D, Bertrand P, Dea D, Davignon J, Poirier J (1996)
Apolipoprotein E and low density lipoprotein binding and
internalization in primary cultures of rat astrocytes: isoform-
specific alterations. J Neurochem 66:2410–2418
Heiba IM, Elston RC, Klein BEK, Klein R (1994) Sibling cor-
relations and segregation analysis of age-related macular de-
generation: the Beaver Dam Eye Study. Genet Epidemiol 11:
51–67
Hofman A, Grobbee DE, de Jong PTVM, van den Ouweland
FA (1991) Determinants and disabilities in the elderly: the
Rotterdam Elderly Study. Eur J Epidemiol 7:403–422
Hoyng CB, Heutink P, Testers L, Pinckers A, Deutman AF,
Oostra BA (1996) Autosomal dominant central areolar cho-
roidal dystrophy caused by a mutation in codon 142 in the
peripherin/RDS gene. Am J Ophthalmol 121:623–629
Ignatius MJ, Gebicke-Harter PJ, Skene JH, Schilling JW, Weis-
graber KH, Mahley RW, Shooter EM (1986) Expression of
apolipoprotein E during nerve degeneration and regenera-
tion. Proc Natl Acad Sci USA 83:1125–1129
Keen TJ, Inglehearn CF, Kim R, Bird AC, Bhattacharya S
(1994) Retinal pattern dystrophy associated with a 4 bp
insertion at codon 140 in the RDS-peripherin gene. Hum
Mol Genet 3:367–368
Kervinen K, Savolainen MJ, Salokannel J, Hynninen A, Heik-
kinen J, Ehnholm C, Koistinen MJ, et al (1994) Apolipo-
protein E and B polymorphisms—longevity factors assessed
in nonagenarians. Atherosclerosis 105:89–95
Klaver CCW, Wolfs RCW, van Duijn CM, Hofman A, de Jong
PTVM (1997) Familial aggregation of age-related macular
degeneration in the Rotterdam Study. Invest Ophthalmol Vis
Sci Suppl 38:S967
Klaver CCW, Wolfs RCW, Vingerling JR, Hofman A, De Jong
PTVM (1998) Age-specific prevalence and causes of blind-
ness and visual impairment in an older population. Arch
Ophthalmol 116:653–658
Klein R, Wang Q, Klein BEK, Moss SE, Meuer SM (1995) The
relationship of age-related maculopathy, cataract and glau-
coma to visual acuity. Invest Ophthalmol Vis Sci 36:
182–191
Kliffen M, van der Schaft TL, Mooy CM, de Jong PTVM
(1997) Morphologic changes in age-related maculopathy.
Microsc Res Tech 36:106–122
Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS (1989)
Low density lipoprotein receptor-related protein mediates
uptake of cholesterol esters derived from apolipoprotein E-
206 Am. J. Hum. Genet. 63:200–206, 1998
enriched lipoproteins. Proc Natl Acad Sci USA 86:
5810–5814
Kuhrt H, Hartig W, Grimm D, Faude F, Kasper M, Reichen-
bach A (1997) Changes in CD44 and apolipoprotein E im-
munoreactivities due to retinal pathology of man and rat. J
Hirnforsch 38:223–229
Mahley RW (1988) Apolipoprotein E: cholesterol transport
protein with expanding role in cell biology. Science 240:
622–630
Nakazawa M, Kikawa E, Chida Y, Tamai M (1994)
Asn244His mutation of the peripherin/RDS gene causing
autosomal dominant cone-rod degeneration. Hum Mol Ge-
net 3:1195–1196
Namba Y, Tomonaga M, Kawasaki H, Otoma E, Ikeda K
(1991) Apolipoprotein E immunoreactivity in cerebral am-
yloid deposits and neurofibrillary tangles in Alzheimer’s dis-
ease and kuru plaque amyloid in Creutzfeld-Jakob disease.
Brain Res 541:163–166
Nichols BE, Sheffield VC, Vandenburgh K, Drack AV, Kimura
AE, Stone EM (1993) Butterfly-shaped pigment dystrophy
of the fovea caused by a point mutation in codon 167 of
the RDS gene. Nat Genet 3:202–206
Olaisen B, Telsberg P, Gedde-Dahl T Jr (1982) The locus for
apolipoprotein E (apoE) is linked to the complement com-
ponent C3 (C3) locus on chromosome 19 in man. Hum
Genet 62:233–236
Pitas RE, Boyles JK, Lee SH, Hui DY, Weisgraber KH (1987)
Lipoproteins and their receptors in the central nervous sys-
tem: characterization of the lipoproteins in cerebrospinal
fluid and identification of apolipoprotein B, E (LDL) recep-
tors in the brain. J Biol Chem 262:14352–14360
Poirier J, Baccichet A, Dea D, Gauthier S (1993) Cholesterol
synthesis and lipoprotein reuptake during synaptic remod-
elling in hippocampus in adult rats. Neuroscience 55:81–90
Poirier J, Minnich A, Davignon J (1995) Apolipoprotein E,
synaptic plasticity and Alzheimer’s disease. Ann Med 27:
663–670
Sarks SH (1976) Aging and degeneration in the macular re-
gion: a clinico-pathological study. Br J Ophthalmol 60:
324–341
Seddon JM, Ajani UA, Mitchell B (1997) Familial aggregation
of age-related maculopathy. Am J Ophthalmol 123:199–206
Small KW, Syrquin M, Mullen L, Gehrs K (1996) Mapping
autosomal dominant cone degeneration to chromosome
17p. Am J Ophthalmol 121:13–18
Small KW, Weber JL, Roses A, Lennon F, Vance JM, Pericak-
Vance P (1992) North Carolina macular dystrophy is as-
signed to chromosome 6. Genomics 13:681–685
Smit M, de Knijff P, Rosseneu M, Bury J, Klasen E, Frants R,
Havekes L (1988) Apolipoprotein E polymorphism in the
Netherlands and its effect on plasma lipid and apolipopro-
tein levels. Hum Genet 80:287–292
Sommer A, Tielsch JM, Katz J, Quickley HA, Gottsch JJ, Javitt
JC, Martone JF, et al (1991) Racial differences in the cause-
specific prevalence of blindness in east Baltimore. N Engl J
Med 325:1412–1417
Stone EM, Nichols BE, Kimura AE, Weingeist TA, Drack A,
Sheffield VC (1994) Clinical features of a Stargardt-like
dominant progressive macular dystrophy with genetic link-
age to chromosome 6q. Arch Ophthalmol 112:765–772
Stone EM, Nichols BE, Streb LM, Kimura AE, Sheffield VC
(1992) Genetic linkage of vitelliform macular degeneration
(Best’s disease) to chromosome 11q13. Nat Genet 1:
246–250
Strittmatter WJ, Saunders AM, Schmechel DE, Pericak-Vance
MA, Enghild J, Salvesen GS, Roses AD (1993) Apolipopro-
tein E: high avidity binding to b-amyloid and increased fre-
quency of type 4 allele in late-onset familial Alzheimer dis-
ease. Proc Natl Acad Sci USA 90:1977–1981
Utermann G (1985) Apolipoprotein E mutants, hyperlipide-
mia, and atherosclerosis. Adv Exp Med Biol 183:173–188
van der Schaft TL, Mooy CM, de Bruijn WC, Orom FG,
Mulder PG, de Jong PTVM (1992) Histologic features of
the early stages of age-related macular degeneration: a sta-
tistical analysis. Ophthalmology 99:278–286
Van Duijn CM, de Knijff P, Cruts M, Wehnert A, Havekes
LM, Hofman A, Van Broeckhoven C (1994) Apolipoprotein
E4 allele in a population-based study of early-onset Alzhei-
mer’s disease. Nat Genet 7:74–78
Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hi-
jmering M, Kramer CFL, de Jong PTVM (1995) The prev-
alence of age-related maculopathy in the Rotterdam Study.
Ophthalmology 102:205–210
Weber BHF, Vogt G, Pruett RC, Stohr H, Felbor U (1994)
Mutations in the tissue inhibitor of metalloproteinases-3
(TIMP3) in patients with Sorsby’s fundus dystrophy. Nat
Genet 8:352–355
Weleber RG, Carr RE, Murphey WH, Sheffield VC, Stone EM
(1993) Phenotypic variation including retinitis pigmentosa,
pattern dystrophy, and fundus flavimaculus in a single family
with a deletion of codon 153 or 154 of the peripheral/RDS
gene. Arch Ophthalmol 111:1531–1542
Wells J, Wroblewski J, Keen J, Inglehearn C, Jubb C, Eckstein
C, Jay M, et al (1993) Mutations in the human retinal de-
generation slow (RDS) gene can either cause retinitis pig-
mentosa or macular dystrophy. Nat Genet 3:213–218
Wenham PR, Price WH, Blundell G (1991) Apoliprotein E
genotyping by one-stage PCR. Lancet 337:1158–1159
Wisniewski T, Frangione B (1992) Apolipoprotein E: a path-
ological chaperone protein in patients with cerebral and sys-
temic amyloid. Neurosci Lett 135:235–238
